Trials / Unknown
UnknownNCT00710229
Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | intravitreal injection |
| DRUG | Bevacizumab | intravitreal injection |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-12-01
- First posted
- 2008-07-04
- Last updated
- 2010-06-09
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00710229. Inclusion in this directory is not an endorsement.